New FDA-Approved Option for HER2-Mutated Lung Cancer

(MedPage Today) — The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The approval stipulates use in patients who already have received systemic therapy for NSCLC. At the same…